COLLABORATION and LICENSE AGREEMENT BY AND BETWEENCollaboration and License Agreement • November 10th, 2020 • Fulcrum Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Collaboration and License Agreement (this “Agreement”) is entered into as of July 20, 2020 (the “Effective Date”), by and between Fulcrum Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (“Fulcrum”), and MyoKardia, Inc., a corporation organized under the laws of the State of Delaware (“MyoKardia”). MyoKardia and Fulcrum each may be referred to herein individually as a “Party” or collectively as the “Parties.”
FIRST AMENDMENT TO THE RIGHT OF REFERENCE AND LICENSE AGREEMENTReference and License Agreement • November 10th, 2020 • Fulcrum Therapeutics, Inc. • Pharmaceutical preparations
This FIRST AMENDMENT TO THE RIGHT OF REFERENCE AND LICENSE AGREEMENT (“Amendment”) is made and entered into, effective as of September 23, 2020, by and between GlaxoSmithKline Intellectual Property (No. 2) Limited, a company organized under the laws of England and Wales and having a place of business at 980 Great West Road, Brentford, Middlesex TW8 9GS England (“GIP2”), GlaxoSmithKline LLC, a Delaware limited liability company having a place of business at 1250 S. Collegeville Road, Collegeville, PA 19426-0989 (“GSK LLC”) and Glaxo Group Limited, a company organized under the laws of England and Wales and having a place of business at 980 Great West Road, Brentford, Middlesex TW8 9GS England (“GGL”; together with GIP2 and GSK LLC”, collectively referred to herein as “GSK”) and Fulcrum Therapeutics, Inc., a Delaware corporation having a place of business at 26 Landsdowne Street, Cambridge, MA 02139 (“Fulcrum”). GSK and Fulcrum are herein collectively referred to as the “Parties”.
